A Randomized Multicenter Open-label Study to Evaluate the Efficacy of Tirofiban Using a High-dose Bolus Plus a Shortened Infusion Duration Versus Label-dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention

Brief Description Of Study

The first primary objective of this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, periprocedural myonecrosis (PPM), urgent target vessel revascularization (uTVR) or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first. The co-primary objectives of this study are to assess whether: (i) a short tirofiban regimen of a high-dose bolus plus a 1-2 hour infusion post procedure compared to a long tirofiban regimen of a high-dose bolus plus a 12-18 hour infusion, and (ii) a long tirofiban regimen of a high-dose bolus plus a 12-18 hour infusion compared to label-dosing eptifibatide, are associated with non-inferior composite rates of death, PPM, uTVR, or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first.

Clinical Study Identifier: 816788

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: A Randomized Multicenter Open-label Study to Evaluate the Efficacy of Tirofiban Using a High-dose Bolus Plus a Shortened Infusion Duration Versus Label-dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.